common.study.topics.clinical

Oral Cholera Vaccine

common.study.values.description

“Immunologic Responses to a Live Attenuated Oral Cholera Vaccine”

The primary objective of this study is to evaluate the antibody response to the cholera vaccine, VaxchoraAR, in healthy subjects. Investigators also seek to evaluate additional markers of the adaptive immune response including plasmablasts, activated B cells, memory B cells, and T cell responses in healthy subjects receiving cholera vaccine, produce monoclonal antibodies against cholera, and evaluate the safety and reactogenicity in healthy subjects receiving cholera vaccine.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Vaxchora

Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

common.study.values.clinical-trial-id

NCT03251495

participant.views.study.view.id

yb8Lob